Seres Therapeutics to Present Clinical Research on the Microbiome’s Impact on Allogeneic Hematopoietic Stem Cell Transplantation and Cancer Immunotherapy at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
- Seres is advancing its microbiome research efforts in oncology to improve patient outcomes following disease treatments -
“Research has shown that disruption in the gut microbiome can affect clinical outcomes in patients treated with certain cancer treatments, including allogeneic hematopoietic stem cell transplantation and cancer immunotherapy,” said
Presentation details are as follows:
-
Oral Abstract Presentation: Prospective longitudinal evaluation of microbiome diversity in patients with hematological malignancy undergoing allogeneic hematopoietic stem cell transplantation (HSCT),
June 4, 2021 , 2:30 –5:30 pm ET , lead co-authors:Emily Walsh , Anastasia Tsakmaklis (Abstract: 7005) -
Poster Presentation: Assessment of cancer-specific microbiome signature of response to immune checkpoint inhibitors, June 4, 2021,
9:00 am ET , lead co-authors:Michal Sarfaty ,Christopher A. Desjardins (Abstract: 2574)
About
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including the potential of microbiome therapeutics to treat and prevent disease or improve the outcomes of cancer patients, the impact of microbiome therapeutics, the ultimate efficacy data for our products; and other statements which are not historical fact.
These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: we have incurred significant losses, are not currently profitable and may never become profitable; our need for additional funding; our limited operating history; the impact of the COVID-19 pandemic; our unproven approach to therapeutic intervention; the lengthy, expensive and uncertain process of clinical drug development; our reliance on third parties and collaborators to conduct our clinical trials, manufacture our product candidates and develop and commercialize our product candidates, if approved; our ability to retain key personnel and to manage our growth; and our management and principal stockholders have the ability to control or significantly influence our business. These and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q filed with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20210519005960/en/
PR Contact
kainsworth@serestherapeutics.com
IR Contact
ctanzi@serestherapeutics.com
Source: